Cargando…
MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
BACKGROUND: MEK and BRAF inhibitors are increasingly common treatments for pediatric nervous system tumors. While effective in blocking Ras/Raf/MEK/ERK pathway activation driving tumor progression, the side effect profile differs from traditional cytotoxic chemotherapies. Little data exists on overl...
Autores principales: | Winzent, Shelby, Sabus, Ashley, Hemenway, Molly, Nellan, Anandani, Mulcahy-Levy, Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715474/ http://dx.doi.org/10.1093/neuonc/noaa222.578 |
Ejemplares similares
-
MODL-01. Targeting replication stress in pediatric brain tumors
por: Krausert, Sonja, et al.
Publicado: (2022) -
MODL-27. MEK INHIBITION WITH TRAMETINIB SLOWS PROGRESSION OF MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR IN ORTHOTOPIC XENOGRAFT MURINE MODEL
por: Mushrif, Sujata, et al.
Publicado: (2020) -
MODL-19. DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL UP- OR DOWN-STREAM INHIBITION
por: Izquierdo, Elisa, et al.
Publicado: (2020) -
MODL-02. TARGETING REPLICATION STRESS IN PEDIATRIC BRAIN TUMORS
por: Krausert, Sonja, et al.
Publicado: (2020) -
MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
por: Sommerkamp, Alexander C, et al.
Publicado: (2020)